Core Viewpoint - The company, Te Yi Pharmaceutical, emphasizes the competitive advantages of its core product, Zhi Ke Bao tablets, which include technological, brand, and efficacy strengths [2]. Group 1: Competitive Advantages - Technological Advantage: The company utilizes advanced extraction processes and quantitative measurement techniques to ensure stable and controllable drug quality. It has applied for multiple invention patents related to the composition, preparation methods, and component testing of Zhi Ke Bao tablets, all of which have been granted, creating a comprehensive patent protection system [2]. - Brand Advantage: Zhi Ke Bao tablets have a century-long history and high market recognition, supported by a loyal customer base [2]. - Efficacy Advantage: Clinical validation shows that Zhi Ke Bao tablets are most effective for treating cold and phlegm-related coughs, with total effective rates of 100% and 95% respectively, while exhibiting low toxicity and quick results [2]. Group 2: Product Strategy - The company is building a "1+N" product matrix centered around Zhi Ke Bao tablets, aiming to continuously enrich its product line and further strengthen its core competitiveness [2].

Core Viewpoint - The company, Te Yi Pharmaceutical, emphasizes the historical significance and efficacy of its core product, Zhi Ke Bao tablets, which have been in use for over a century and are known for their benefits in "clearing the lungs, dispelling phlegm, relieving cough, and alleviating asthma" [2] Company Summary - Te Yi Pharmaceutical's core product, Zhi Ke Bao tablets, has a history of over 100 years [2] - The product is recognized for its therapeutic effects, including lung clearance, phlegm dispelling, cough relief, and asthma alleviation [2]

Core Insights - The company has reported significant growth in revenue and net profit for the first three quarters of 2025, with total revenue reaching 692 million yuan, a year-on-year increase of 51.86% [1] - The net profit attributable to shareholders was 65.22 million yuan, reflecting a remarkable year-on-year growth of 985.18% [1] - Sales of the core product, "Te Yi" cough tablets, have steadily recovered, achieving 64% of the sales volume compared to the same period in 2023 [1] - The company has made positive progress in expanding its online business [1] - The operational performance for 2025 is in line with the company's internal planning expectations [1] - The finance department is currently conducting annual financial accounting in an orderly manner [1] - The company will fulfill its information disclosure obligations in a timely manner based on the financial accounting results [1]

Core Viewpoint - The company has not yet ventured into the "Traditional Chinese Medicine + Brain-Computer Interface" sector but will continue to monitor technological developments in this area [1] Group 1 - The company currently does not have any business layout related to "Traditional Chinese Medicine + Brain-Computer Interface" [1] - The company will adhere to information disclosure rules and fulfill announcement obligations if there are future business plans in this field [1]

Group 1 - The company, Te Yi Pharmaceutical (002728.SZ), currently does not have any products related to hyperbaric oxygen chambers [1]

Group 1 - The company approved the temporary use of up to RMB 25 million of idle funds from convertible bonds to supplement working capital, aiming to improve fund utilization efficiency and reduce financial costs [1] - As of January 6, 2026, the company has repaid RMB 6 million of the temporarily supplemented working capital back to the dedicated account for convertible bond funds, with a total of RMB 11 million repaid to date [2] - The remaining RMB 14 million of idle funds is expected to be repaid before the due date, and the company will disclose information if the balance in the dedicated account cannot meet normal payment needs [2]

关于提前归还可转债部分暂时补充流动资金的募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 截至目前，公司已累计归还 1,100 万元资金至可转债募集资金专用账户，剩余暂时 补充流动资金的 1,400 万元闲置募集资金将在到期之前归还。在此期间如遇可转债募集 资金专用账户余额不能满足募集资金正常支付的情况，公司将根据实际需要将已补充流 动资金的募集资金提前归还至可转债募集资金专用账户，届时公司将及时履行信息披露 义务。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 5 月 21 日召开第五届董事会第三十二次会议，审议通过了《关于使用可转债部分闲置募集资 金暂时补充流动资金的议案》，为了有效提高募集资金的使用效率，减少财务费用，降 低运营成本，维护公司和股东利益，在确保公司可转换公司债券募集资金投资项目按进 度实施的前提下，同意公司使用不超过人民币 2,500 万元可转债闲置募集资金暂时补充 流动资金，董事会审议通过后，自首次办理暂时补充流动资金之日起，不超过 12 个月， 到期前归还至募集资金专用账户。具体内容详见公司 ...

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - The company is committed to dual-track research in traditional Chinese medicine (TCM) and chemical drugs, aiming to enhance product quality and market competitiveness through innovation [1] Group 1: Traditional Chinese Medicine (TCM) Development - The company is focusing on the inheritance and development of existing TCM products, conducting clinical and real-world studies for secondary development of key TCM products [1] - The goal is to grow distinctive TCM products, such as cough tablets, skin disease blood detox pills, and blood sugar-lowering pills, into major TCM varieties to enhance brand influence [1] - The company is actively seizing opportunities in the TCM industry by strengthening collaborations with relevant research institutions to develop innovative TCM drugs [1] Group 2: Chemical Drug Research - The company is conducting integrated innovation research on "active pharmaceutical ingredients + formulations," focusing on cutting-edge research for drugs treating major diseases [1] - The approach involves a synergistic model of developing both formulations and active pharmaceutical ingredients to improve overall research efficiency [1]